Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP)

被引:29
作者
Bainbridge, Travis W. [1 ]
Dunshee, Diana Ronai [2 ]
Kljavin, Noelyn M. [3 ]
Skelton, Nicholas J. [4 ]
Sonoda, Junichiro [2 ,5 ]
Ernst, James A. [1 ,6 ]
机构
[1] Genentech Inc, Prot Chem, San Francisco, CA 94080 USA
[2] Genentech Inc, Mol Biol, San Francisco, CA 94080 USA
[3] Genentech Inc, Mol Oncol, San Francisco, CA 94080 USA
[4] Genentech Inc, Discovery Chem, San Francisco, CA 94080 USA
[5] Genentech Inc, Canc Immunol, San Francisco, CA 94080 USA
[6] Genentech Inc, Neurosci, San Francisco, CA 94080 USA
来源
SCIENTIFIC REPORTS | 2017年 / 7卷
关键词
INHIBITING ENZYMATIC CLEAVAGE; PROLYL OLIGOPEPTIDASE; DIPEPTIDYL PEPTIDASE; REMODELING INTERFACE; EXPRESSION; IDENTIFICATION; FIBRINOLYSIS; ENHANCEMENT; SPECIFICITY; FIBROSIS;
D O I
10.1038/s41598-017-12900-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Fibroblast Activation Protein (FAP) is a membrane-bound serine protease whose expression is often elevated in activated fibroblasts associated with tissue remodeling in various common diseases such as cancer, arthritis and fibrosis. Like the closely related dipeptidyl peptidase DPPIV, the extracellular domain of FAP can be released into circulation as a functional enzyme, and limited studies suggest that the circulating level of FAP correlates with the degree of tissue fibrosis. Here we describe a novel homogeneous fluorescence intensity assay for circulating FAP activity based on a recently identified natural substrate, FGF21. This assay is unique in that it can effectively distinguish endopeptidase activity of FAP from that of other related enzymes such as prolyl endopeptidase (PREP) and was validated using Fap-deficient mice. Structural modeling was used to elucidate the mechanistic basis for the observed specificity in substrate recognition by FAP, but not by DPPIV or PREP. Finally, the assay was used to detect elevated FAP activity in human patients diagnosed with liver cirrhosis and to determine the effectiveness of a chemical inhibitor for FAP in mice. We propose that the assay presented here could thus be utilized for diagnosis of FAP-related pathologies and for the therapeutic development of FAP inhibitors.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Cardiac Applications of Fibroblast Activation Protein Imaging
    Diekmann, Johanna
    Bengel, Frank M.
    PET CLINICS, 2023, 18 (03) : 389 - 396
  • [32] Evaluation of the circulating level of fibroblast activation protein a for diagnosis of esophageal squamous cell carcinoma
    Liao, Yuehua
    Xing, Shan
    Xu, Banglao
    Liu, Wanli
    Zhang, Ge
    ONCOTARGET, 2017, 8 (18) : 30050 - 30062
  • [33] Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators
    Moon, Euy Sung
    Elvas, Filipe
    Vliegen, Gwendolyn
    De Lombaerde, Stef
    Vangestel, Christel
    De Bruycker, Sven
    Bracke, An
    Eppard, Elisabeth
    Greifenstein, Lukas
    Klasen, Benedikt
    Kramer, Vasko
    Staelens, Steven
    De Meester, Ingrid
    Van der Veken, Pieter
    Roesch, Frank
    EJNMMI RADIOPHARMACY AND CHEMISTRY, 2020, 5 (01)
  • [34] Sound and Fibroblast Activation Protein Inhibitor Imaging Fibroblast Activation in the Heart
    Thackeray, James T.
    CIRCULATION-CARDIOVASCULAR IMAGING, 2020, 13 (09)
  • [35] Beta-endoproteolysis of the cellular prion protein by dipeptidyl peptidase-4 and fibroblast activation protein
    Castle, Andrew R.
    Kang, Sang-Gyun
    Eskandari-Sedighi, Ghazaleh
    Wohlgemuth, Serene
    Nguyen, My-Anh
    Drucker, Daniel J.
    Mulvihill, Erin E.
    Westaway, David
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (01)
  • [36] Fibroblast activation protein (FAP) as a prognostic biomarker in multiple tumors and its therapeutic potential in head and neck squamous cell carcinoma
    Li, Ruifang
    Nan, Xinrong
    Li, Ming
    Rahhal, Omar
    ONCOLOGY RESEARCH, 2024, 32 (08) : 1323 - 1334
  • [37] Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease
    de Willige, Shirley Uitte
    Keane, Fiona M.
    Bowen, David G.
    Malfliet, Joyce J. M. C.
    Zhang, H. Emma
    Maneck, Bharvi
    McCaughan, Geoffrey W.
    Leebeek, Frank W. G.
    Rijken, Dingeman C.
    Gorrell, Mark D.
    PLOS ONE, 2017, 12 (06):
  • [38] Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2-Pro1-cleaving specificity
    Edosada, CY
    Quan, C
    Tran, T
    Pham, V
    Wiesmann, C
    Fairbrother, W
    Wolf, BB
    FEBS LETTERS, 2006, 580 (06) : 1581 - 1586
  • [39] Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate
    Huang, Chih-Hsiang
    Suen, Ching-Shu
    Lin, Ching-Ting
    Chien, Chia-Hui
    Lee, Hsin-Ying
    Chung, Kuei-Min
    Tsai, Ting-Yueh
    Jiaang, Weir-Tong
    Hwang, Ming-Jing
    Chen, Xin
    JOURNAL OF BIOCHEMISTRY, 2011, 149 (06) : 685 - 692
  • [40] Fibroblast activating protein promotes the proliferation, migration, and activation of fibroblasts in oral submucous fibrosis
    Li, Ming
    Deng, Zhiyuan
    Xie, Changqin
    Chen, Juan
    Yuan, Zhenying
    Rahhal, Omar
    Tang, Zhangui
    ORAL DISEASES, 2024, 30 (03) : 1252 - 1263